Cordasco Financial Network’s CRISPR Therapeutics CRSP Stock Holding History

Cordasco Financial Network’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$1K	Buy	+20	New	+$1.18K	﹤0.01%	549

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Cordasco Financial Network's CRSP Position: Q2 2022 in Review

Cordasco Financial Network opened a new position in CRISPR Therapeutics (CRSP) in Q2 2022: 20 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #549 among its holdings.

435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

Cordasco Financial Network held 20 shares of CRISPR Therapeutics worth $1K as of Q2 2022.
CRISPR Therapeutics was a new Cordasco Financial Network position in Q2 2022.
CRISPR Therapeutics made up ﹤0.01% of Cordasco Financial Network's portfolio in Q2 2022, its #549 holding.
435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Cordasco Financial Network's 13F filing for Q2 2022, filed 15 Jul 2022.